Compare CHR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | UNCY |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.4M | 126.4M |
| IPO Year | N/A | 2021 |
| Metric | CHR | UNCY |
|---|---|---|
| Price | $1.59 | $6.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | ★ 387.8K | 357.9K |
| Earning Date | 07-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 96.06 | N/A |
| Revenue | ★ $147,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $3.71 |
| 52 Week High | $141.71 | $11.00 |
| Indicator | CHR | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 79.11 | 56.66 |
| Support Level | $1.30 | $5.36 |
| Resistance Level | $1.65 | $5.95 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 94.08 | 80.30 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.